SPRINGWORKS THERAPEUTICS INC's ticker is SWTX and the CUSIP is 85205L107. A total of 134 filers reported holding SPRINGWORKS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,079,000 | -2.0% | 46,646 | +11.1% | 0.00% | – |
Q2 2023 | $1,101,000 | +54.4% | 41,987 | +51.7% | 0.00% | – |
Q1 2023 | $713,000 | -5.2% | 27,677 | -4.5% | 0.00% | – |
Q4 2022 | $752,000 | -0.8% | 28,967 | +9.0% | 0.00% | – |
Q3 2022 | $758,000 | +22.5% | 26,581 | +5.8% | 0.00% | – |
Q2 2022 | $619,000 | -58.6% | 25,134 | -5.0% | 0.00% | – |
Q1 2022 | $1,494,000 | -7.2% | 26,465 | +1.8% | 0.00% | – |
Q4 2021 | $1,610,000 | +61.6% | 25,986 | +65.5% | 0.00% | – |
Q3 2021 | $996,000 | +303.2% | 15,702 | +425.3% | 0.00% | – |
Q2 2021 | $247,000 | +6.9% | 2,989 | -4.9% | 0.00% | – |
Q1 2021 | $231,000 | +260.9% | 3,142 | +259.9% | 0.00% | – |
Q4 2020 | $64,000 | +88.2% | 873 | +21.6% | 0.00% | – |
Q3 2020 | $34,000 | +9.7% | 718 | -4.0% | 0.00% | – |
Q2 2020 | $31,000 | +55.0% | 748 | +0.3% | 0.00% | – |
Q1 2020 | $20,000 | – | 746 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 5,831,307 | $480,558,000 | 31.49% |
Consonance Capital Management LP | 1,199,339 | $98,838,000 | 11.90% |
Boxer Capital, LLC | 2,075,905 | $171,075,000 | 6.04% |
Perceptive Advisors | 9,699,824 | $799,362,000 | 5.19% |
Orbimed Advisors | 6,044,266 | $498,108,000 | 5.04% |
Samsara BioCapital, LLC | 169,852 | $13,998,000 | 1.73% |
DRIEHAUS CAPITAL MANAGEMENT LLC | 1,375,775 | $113,378,000 | 1.50% |
SPHERA FUNDS MANAGEMENT LTD. | 195,117 | $16,080,000 | 1.09% |
Artal Group S.A. | 500,000 | $41,205,000 | 0.84% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 558,574 | $46,032,000 | 0.82% |